Abstract: A method of measuring physiological function of a group of body cells, includes the step of selecting a detectable agent capable of emitting a measurable electromagnetic emission. The agent is introduced into body fluid which contacts the group of body cells. The emission is measured, and physiological function is determined based on measurement of the emission.
Type:
Grant
Filed:
March 13, 1997
Date of Patent:
July 27, 1999
Assignees:
Mallinckrodt Inc., Washington University
Inventors:
Richard B. Dorshow, Joseph E. Bugaj, B. Daniel Burleigh, James R. Duncan, Michael Anthony Johnson, William B. Jones
Abstract: This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to peptides, methods and kits for making such peptides, and methods for using such peptides to image sites in a mammalian body labeled with technetium-99m (Tc-99m) via a radiolabel-binding moiety which forms a neutral complex with Tc-99m.
Type:
Grant
Filed:
June 6, 1995
Date of Patent:
July 13, 1999
Assignee:
Diatide, Inc.
Inventors:
Richard T. Dean, Scott Buttram, William McBride, John Lister-James, Edgar R. Civitello
Abstract: There is provided a diagnostic for central nervous abnormality, comprising a labeled transmitter substance of central nervous system or a labeled precursor of the transmitter substance, whose at least one of carbon atoms is substituted for a carbon isotope wherein the diagnostic is useful for diagnosing a central nervous abnormality (e.g. depression, Alzheimer's disease, schizophrenia, etc.) by applying it to a living body by oral administration or injection and examining a change in an amount of the carbon isotope in a breath of the living body.
Abstract: Radioactive arsenic (.sup.72 As) labelled tissue specific ligands are prepared and used in the medical imaging of malignant breast or prostate tumors.
Abstract: Administrable factors or compositions to be directed to specific sites in the body of human and animal patients which comprise a medically and/or diagnostically effective moiety (I) and, coupled thereto by means of a linker (L), a substance (II) having specific affinity for specific sites in the organism.Linker "L" has a structure schematized by the formula:Y(W-Z-R).sub.m, m being 1, 2, or 4wherein the portion YW is an amphiphile, i.e. a segment comprised of a hydrophobic-lipophilic sequence "Y" and a hydrophilic-lipophobic sequence "W" connected covalently together, Z is a chemical bond or an intermediate connector sequence and R is a reactive function for effecting coupling with selected substances (II).
Type:
Grant
Filed:
October 31, 1996
Date of Patent:
June 8, 1999
Assignee:
Bracco Research S.A.
Inventors:
Herve Tournier, Sibylle Pochon, Bernard Lamy
Abstract: Multicyclic nitrone spin trapping compounds capable of forming stable free radical spin adducts are provided as well as methods for their synthesis. The multicyclic nitrone spin trapping compounds can be reacted with a free radical, such as a hydroxy or hydroperoxy radical, in solution to form a spin adduct which is stable and readily detectable by electron paramagnetic resonance (EPR) spectroscopy. The multicyclic nitrone spin traps can be used to detect free radicals in a sample such as a biological system. In one embodiment, the spin trapping compound, 1,3,3-trimethyl-6-azabicyclo-?3.2.1!oct-6-ene-N-oxide ("TRAZON") is provided, as well as methods for the synthesis of TRAZON and of modified forms of TRAZON. TRAZON can react with a wide range of different free radicals in solution to form free radical spin adducts which are readily detectable by EPR.
Abstract: Disclosed is a vaccine against an infective agent, the vaccine comprising a liposome having an exterior and an interior and having externally disposed affinity associated antigen material of at least one, preferably nonpartitioning, antigen representative of said infective agent. Also disclosed is a method of preparation and use of this vaccine.
Abstract: The present invention relates to a vaccine container that contains one or more freeze-dried vaccine components. The vaccine component or components are present in two or more freeze-dried bodies, at least one of which is a lyosphere.Furthermore, the invention relates to methods for the preparation of such a vaccine container.Also, the invention relates to a vaccine pack, comprising the vaccine container.
Type:
Grant
Filed:
February 21, 1997
Date of Patent:
April 27, 1999
Assignee:
Akzo Nobel, N.V.
Inventors:
Antonius Theodorus Maria Wilderbeek, Hans Almer Middelbeek
Abstract: This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to specific binding peptides, methods and kits for making such peptides, and methods for using such peptides labeled with technetium-99m via a radiolabel-binding moiety covalently linked to the peptide to image thrombus sites in a mammalian body.
Abstract: The present invention provides compositions comprising contrast agents capable of binding non-covalently to blood proteins. The compositions of the invention provide increased residence time of contrast agents in the vasculature, thus providing effective blood pool contrast agents. The invention also provides methods for imaging a patient comprising administering a composition of the invention to a patient and obtaining an image.
Abstract: A particulate material which comprises hollow or cup-shaped ceramic microspheres having a diameter in the range of from 5 to 200 microns. The material may comprise a beta- or gamma-emitting radionuclide and be used in selective internal radiation therapy (SIRT) of various forms of cancer and tumours.
Abstract: Disclosed is a method for measuring the effectiveness of therapy intended to kill malignant cells in vivo in a mammal, comprising the steps of obtaining monoclonal antibody that is specific to an internal cellular component of the mammal but not to external cellular components, wherein the monoclonal antibody is labeled; contacting the labeled antibody with tissue of a mammal that has received therapy to kill malignant cells in vivo, and determining the effectiveness of the therapy by measuring the binding of the labeled antibody to the internal cellular component. The internal cellular component is preferably insoluble intracellular antigen, and the label is preferably a radionuclide, a radiopaque material, or a magnetic resonance-enhancing material. Also disclosed is a method whereby the antibody to insoluble intracellular antigen is conjugated to an antineoplastic agent, so that upon administration of the antibody-antineoplastic agent conjugate, antineoplastic agent may be delivered to the tumor.
Abstract: This invention provides novel radiopharmaceuticals that are radiolabeled cyclic compounds containing carbocyclic or heterocyclic ring systems which act as antagonists of the platelet glycoprotein IIb/IIIa complex; to methods of using said radiopharmaceuticals as imaging agents for the diagnosis of arterial and venous thrombi; to novel reagents for the preparation of said radiopharmaceuticals; and to kits comprising said reagents.
Type:
Grant
Filed:
March 28, 1994
Date of Patent:
March 9, 1999
Assignee:
The Dupont Merck Pharmaceutical Company
Inventors:
William Frank DeGrado, Shaker Ahmed Mousa, Michael Sworin, John Andrew Barrett, Scott David Edwards, Thomas David Harris, Milind Rajopadhye, Shuang Liu
Abstract: This invention relates to radiolabeled peptides and methods for producing such peptides. Specifically, the invention relates to specific binding peptides, methods and kits for making such peptides, and methods for using such peptides labeled with technetium-99m via a radiolabel-binding moiety covalently linked to the peptide to image thrombus sites in a mammalian body.
Abstract: The nucleoside analog 2'-fluoro-5-methyl-1-.beta.-D-arabinofuranosyluracil (FMAU) has been found to have an especially desirable combination of properties for use as an imaging agent, including in particular limited in vivo catabolism. Methods for the preparation of the ?.sup.11 C!-labelled FMAU and for the use of the labelled material are also provided.
Type:
Grant
Filed:
August 23, 1995
Date of Patent:
March 9, 1999
Assignee:
University Advanced Bio-Imaging Associates
Inventors:
Peter S. Conti, Mian M. Alauddin, John D. Fissekis
Abstract: This invention relates to radiodiagnostic agents and reagents for preparing such agents, and also methods for producing radiolabeled radiodiagnostic agents. Specifically, the invention relates to technetium-99m (.sup.99m Tc) labeled agents, methods and kits for making the agents, and methods for using the agents to image pathological sites, including sites of infection, inflammation, cancer and atherosclerosis in a mammalian body. Specifically the agents and reagents are derivatives of oligosaccharides, more specifically .beta.-glucans.
Abstract: Polymeric compounds of general formula I(M).sub.n A (I)in whichM stands for the radical of a macrocyclic complexing agent,A stands for a backbone molecule, which shows a deficit of n amino groups, n hydroxy groups or n carboxy groups,n stands for the numbers 1 to 400, characterized in thatM, independent of one another, stands for complexing agents of general formula IA ##STR1## in which all variables are defined herein.
Type:
Grant
Filed:
May 11, 1992
Date of Patent:
March 2, 1999
Assignee:
Schering Aktiengesellschaft
Inventors:
Heribert Schmitt-Willich, Johannes Platzek, Heinz Gries, Gabriele Schuhmann-Giampieri, Thomas Frenzel
Abstract: A bioaerosol collection device (BCD) includes a housing with a first opening, a second opening, and a plate positioned between the first opening and the second opening. When a vacuum is applied to the second opening, the resulting air flow through the BCD causes bioaerosols to collect on a medium positioned on a surface of the plate. The collected bioaerosols are incubated and the resulting bacterial colonies can then be counted to determine a level of bioaerosol contamination in the air.
Abstract: The invention relates to radiolabeled imaging of a mammalian body. The invention in particular provides for reagents labeled with technetium-99m for such imaging. The invention provides peptides which bind Tc-99m and which can be targeted to specific sites within a mammalian body.
Type:
Grant
Filed:
October 28, 1994
Date of Patent:
February 2, 1999
Assignee:
Diatide, Inc.
Inventors:
Richard T. Dean, William McBride, Scott Buttram
Abstract: There is disclosed a diagnostic imaging agent which comprises a compound wherein at least one bifunctional ligand is chemically bonded to an amino group of amino oligosaccharide having the molecular weight of 500 to 2000 and having a reduction-treated reducing end of a sugar chain, or to an aldehyde group of a dialdehyde-oligosaccharide, at least one constituent monosaccharide of which is oxidation-cleaved, having the molecular weight of 500 to 2000 and having a reduction-treated reducing end of a sugar chain, and said ligand is coordinated with at least one metal ion selected from the group consisting of metal ions having the atomic number of 21-29, 31, 32, 37-39, 42-44, 49 and 56-83.
Type:
Grant
Filed:
October 18, 1995
Date of Patent:
January 26, 1999
Assignee:
Nihon Medi-Physics Co., Ltd.
Inventors:
Yuji Hashiguchi, Hideki Sugino, Kenji Kamimura, Shigemi Seri